找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Mechanisms of Drug Resistance in Cancer Therapy; Mario Mandalà,Emanuela Romano Book 2018 Springer Nature Switzerland AG 2018 Drug resistan

[復(fù)制鏈接]
樓主: 非決定性
21#
發(fā)表于 2025-3-25 06:10:37 | 只看該作者
Mechanisms of Resistance in Multiple Myeloma,medullary sites. Multi-modality approaches including “novel agents,” traditional chemotherapy, and/or stem cell transplantation are used in MM therapy. Drug resistance, however, ultimately develops and the disease remains incurable for the vast majority of patients. In this chapter, we review both t
22#
發(fā)表于 2025-3-25 09:33:20 | 只看該作者
23#
發(fā)表于 2025-3-25 14:15:05 | 只看該作者
Mario Mandalà,Emanuela RomanoGives an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.Provides extensive discussions of issues including pharmacodynamic and pharmacokinetic mecha
24#
發(fā)表于 2025-3-25 16:00:36 | 只看該作者
Handbook of Experimental Pharmacologyhttp://image.papertrans.cn/m/image/628714.jpg
25#
發(fā)表于 2025-3-25 21:46:56 | 只看該作者
https://doi.org/10.1007/978-3-030-10507-5Drug resistance; Drug mechanisms; Targeted therapy; Immunotherapy; Chemotherapy; antibacterial drug resis
26#
發(fā)表于 2025-3-26 01:00:23 | 只看該作者
Springer Nature Switzerland AG 2018
27#
發(fā)表于 2025-3-26 06:31:37 | 只看該作者
28#
發(fā)表于 2025-3-26 12:01:27 | 只看該作者
Book 2018 rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities..
29#
發(fā)表于 2025-3-26 13:25:49 | 只看該作者
Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival,research have suggested that the intrinsic pro-survival signaling crosstalk is the driving force in acquired resistance to a targeted therapy, which may be abolished by interfering with the cross-reacting network.
30#
發(fā)表于 2025-3-26 20:24:37 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-16 08:38
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
化德县| 铜陵市| 桐城市| 土默特右旗| 菏泽市| 同德县| 乐都县| 安多县| 应城市| 宣城市| 荃湾区| 聊城市| 石景山区| 潼关县| 寿宁县| 仁怀市| 彰武县| 辉县市| 云梦县| 越西县| 射阳县| 布拖县| 榕江县| 出国| 大丰市| 乐昌市| 应用必备| 广昌县| 乌拉特中旗| 两当县| 滦南县| 鄱阳县| 彰武县| 龙井市| 即墨市| 阜阳市| 罗山县| 武隆县| 洛隆县| 革吉县| 阿合奇县|